AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32912103 — intervention group
Group type: EXPERIMENTAL
Intervention: Interference with daily activities
Number of subjects: 14155
Study 32467522 — intervention group
Group type: EXPERIMENTAL
Intervention: IV ketorolac (60 mg/2 ml)
Number of subjects: 55
Study 32467522 — intervention group
Group type: COMPARATOR
Intervention: Control (IV saline bolus)
Number of subjects: 55
Study 32324477 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein supplementation plus resistive vibration exercise (NeX)
Number of subjects: 12
Study 32324477 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistive vibration exercise (RVE)
Number of subjects: 12
Study 32324477 — intervention group
Group type: COMPARATOR
Intervention: No-intervention control (CNT)
Number of subjects: 12
Study 32324477 — intervention group
Group type: COMPARATOR
Intervention: No intervention (CNT)
Number of subjects: 12
Study 35427803 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 10‐mg/ml
Number of subjects: 220
Study 35427803 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 40‐mg/ml
Number of subjects: 220
Study 35427803 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS 100‐mg/ml
Number of subjects: 220
Study 35427803 — intervention group
Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab 0.5‐mg injections
Number of subjects: 220
Study 35427803 — intervention group
Group type: COMPARATOR
Intervention: PDS 100‐mg/ml vs Monthly ranibizumab
Number of subjects: 220
Study 34389780 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ) 50 mg
Number of subjects: 51
Study 34389780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 33228382 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based adapted physical activity (APA) during adjuvant care (group A)
Number of subjects: 94
Study 33228382 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based adapted physical activity (APA) after adjuvant care (group B)
Number of subjects: 94
Study 33228382 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based adapted physical activity (APA) during and after specific care (group C)
Number of subjects: 94
Study 33228382 — intervention group
Group type: COMPARATOR
Intervention: Comparison of group A and C vs group B
Number of subjects: 94
Study 33228382 — intervention group
Group type: COMPARATOR
Intervention: Control group (no APA)
Number of subjects: 94
Study 35941817 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal adjustment enhancement program using mobile-based education for 4 weeks
Number of subjects: 45
Study 35941817 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 33764642 — intervention group
Group type: EXPERIMENTAL
Intervention: PO‐001 (sustained-release cysteamine bitartrate) 600 mg
Number of subjects: 0
Study 33764642 — intervention group
Group type: COMPARATOR
Intervention: Cystagon® (immediate-release cysteamine)
Number of subjects: 0
Study 33764642 — intervention group
Group type: COMPARATOR
Intervention: Procysbi® (delayed-release cysteamine)
Number of subjects: 0
Study 32020706 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks Circuit Resistance Training (CRT)
Number of subjects: 51
Study 32020706 — intervention group
Group type: COMPARATOR
Intervention: Non-exercising wait-list control
Number of subjects: 51
Study 32102263 — intervention group
Group type: EXPERIMENTAL
Intervention: Beetroot juice (BJ) 70 mL
Number of subjects: 13
Study 32102263 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 13
Study 36368262 — intervention group
Group type: EXPERIMENTAL
Intervention: Defatted flaxseed flour biscuits
Number of subjects: 51
Study 36368262 — intervention group
Group type: COMPARATOR
Intervention: Control biscuits
Number of subjects: 51
Study 34407579 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional axillary dissection based on lymphatic drainage (FUND)
Number of subjects: 168
Study 34407579 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 168
Study 33096810 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie-restricted high protein diet (HPD) (30% calorie intake)
Number of subjects: 80
Study 33096810 — intervention group
Group type: COMPARATOR
Intervention: Calorie-restricted normal protein diet (NPD) (15% calorie intake)
Number of subjects: 80
Study 33096810 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (HPD and NPD)
Number of subjects: 80
Study 34980260 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 577
Study 34980260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 577
Study 33499913 — intervention group
Group type: EXPERIMENTAL
Intervention: IXE Q4W monotherapy
Number of subjects: 455
Study 33499913 — intervention group
Group type: COMPARATOR
Intervention: IXE with concomitant MTX
Number of subjects: 455
Study 33499913 — intervention group
Group type: EXPERIMENTAL
Intervention: IXE Q2W monotherapy
Number of subjects: 455
Study 35157727 — intervention group
Group type: COMPARATOR
Intervention: Standard secondary distribution (control) group
Number of subjects: 309
Study 35157727 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary distribution with monetary incentives (SD-M) group
Number of subjects: 309
Study 35157727 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary distribution with monetary incentives plus peer referral (SD-M-PR) group
Number of subjects: 309
Study 34538333 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafast SARS-CoV-2 viral enrichment and enzymatic extraction method
Number of subjects: 0
Study 32307932 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of low-level laser therapy (LLLT) 1 hour before the insertion of elastomeric separators
Number of subjects: 36
Study 32307932 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of low-level laser therapy (LLLT) 1 hour before and immediately after the insertion of elastomeric separators
Number of subjects: 36
Study 33143559 — intervention group
Group type: EXPERIMENTAL
Intervention: ANDALE intervention (10-week home-based obesity prevention program)
Number of subjects: 50
Study 33241302 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted minimally invasive esophagectomy (RAMIE)
Number of subjects: 109
Study 33241302 — intervention group
Group type: COMPARATOR
Intervention: Open transthoracic esophagectomy (OTE)
Number of subjects: 109
Study 35348875 — intervention group
Group type: EXPERIMENTAL
Intervention: MedDiet
Number of subjects: 802
Study 35348875 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet
Number of subjects: 802
Study 34181361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 44
Study 34181361 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 44
Study 32893026 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography feedback with verbal guidance
Number of subjects: 20
Study 32893026 — intervention group
Group type: COMPARATOR
Intervention: Verbal guidance alone
Number of subjects: 20
Study 35019731 — intervention group
Group type: EXPERIMENTAL
Intervention: Cladribine tablets
Number of subjects: 0
Study 35019731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 33274683 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU)
Number of subjects: 0
Study 33274683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34537623 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin (OT)
Number of subjects: 61
Study 34537623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 32087339 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR) for 8 weeks
Number of subjects: 0
Study 32087339 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram for 8 weeks
Number of subjects: 0
Study 32087339 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0
Study 32087339 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 0
Study 35086493 — intervention group
Group type: EXPERIMENTAL
Intervention: PTSD group
Number of subjects: 32
Study 35086493 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 33754212 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured stress management program (8-week duration)
Number of subjects: 61
Study 33754212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 61
Study 35678643 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral malaria (CM)
Number of subjects: 156
Study 35678643 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe malarial anemia (SMA)
Number of subjects: 156
Study 35678643 — intervention group
Group type: COMPARATOR
Intervention: Community children (CC)
Number of subjects: 156
Study 35678643 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxidative stress biomarkers
Number of subjects: 156
Study 34119067 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone or with chemotherapy
Number of subjects: 0
Study 34119067 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab with chemotherapy
Number of subjects: 0
Study 32761955 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-9701
Number of subjects: 144
Study 32761955 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 35264216 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic liver resection
Number of subjects: 250
Study 35264216 — intervention group
Group type: COMPARATOR
Intervention: Open liver resection
Number of subjects: 250
Study 34780486 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Anaesthetic Care Unit (PACU) pathway with SAMPE model
Number of subjects: 5333
Study 34780486 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (no intervention)
Number of subjects: 5333
Study 35496038 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (AER)
Number of subjects: 20
Study 35496038 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (COM)
Number of subjects: 20
Study 35496038 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (RES)
Number of subjects: 20
Study 35496038 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 20
Study 33172240 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux‐en‐Y gastric bypass
Number of subjects: 135
Study 33172240 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle intervention
Number of subjects: 135
Study 36385378 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA Fillapex
Number of subjects: 88
Study 36385378 — intervention group
Group type: COMPARATOR
Intervention: AH Plus
Number of subjects: 88
Study 34560503 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised machine learning methods for artefact detection in FOT measurements
Number of subjects: 155
Study 34560503 — intervention group
Group type: COMPARATOR
Intervention: Manual breath selection by trained operators
Number of subjects: 155
Study 32424361 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic administration of a single amino acid to experimentally infected mice
Number of subjects: 0
Study 32424361 — intervention group
Group type: COMPARATOR
Intervention: Experimental malaria (control group)
Number of subjects: 0
Study 35762397 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app
Number of subjects: 138
Study 35762397 — intervention group
Group type: COMPARATOR
Intervention: Printed brochures
Number of subjects: 138
Study 33993746 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 33993746 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 33993746 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rating strategy
Number of subjects: 0
Study 32545555 — intervention group
Group type: EXPERIMENTAL
Intervention: High meat and refined grains diet (HMD)
Number of subjects: 51
Study 32545555 — intervention group
Group type: COMPARATOR
Intervention: Energy-matched diet high in whole grain, dairy, nuts and legumes (HWD)
Number of subjects: 51
Study 35863012 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery (n=84)
Number of subjects: 391
Study 35863012 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (n=84)
Number of subjects: 391
Study 33016306 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy-decreasing drinking group (n = 255, 27.27%)
Number of subjects: 935
Study 33016306 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-stable drinking group (n = 353, 37.75%)
Number of subjects: 935
Study 33016306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-stable drinking group (n = 327, 34.97%)
Number of subjects: 935
Study 32871910 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Mahuang-Fuzi-Xixin decoction
Number of subjects: 180
Study 32871910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 34611052 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 6 mg/kg of body mass
Number of subjects: 16
Study 34611052 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) (maltodextrin)
Number of subjects: 16
Study 34611052 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 16
Study 33648441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.6μg/kg
Number of subjects: 120
Study 33648441 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.8μg/kg
Number of subjects: 120
Study 33648441 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 120
Study 32819465 — intervention group
Group type: EXPERIMENTAL
Intervention: PADN (Pulmonary artery denervation)
Number of subjects: 50
Study 32819465 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy with riociguat (MED group)
Number of subjects: 50
Study 32819465 — intervention group
Group type: EXPERIMENTAL
Intervention: PADN
Number of subjects: 50
Study 32819465 — intervention group
Group type: COMPARATOR
Intervention: MED group
Number of subjects: 50
Study 36336248 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally-administered system-wide implementation + local-tailored implementation
Number of subjects: 12
Study 36336248 — intervention group
Group type: COMPARATOR
Intervention: Centrally-administered system-wide implementation only
Number of subjects: 12
Study 34334377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 21
Study 34837418 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination tablet of mosapride 5 mg, pancreatin 170 mg, and simethicone 125 mg
Number of subjects: 65
Study 34837418 — intervention group
Group type: COMPARATOR
Intervention: Single-component mosapride tablets (reference product)
Number of subjects: 65
Study 34729851 — intervention group
Group type: EXPERIMENTAL
Intervention: PROVIDENT model predictions
Number of subjects: 0
Study 34729851 — intervention group
Group type: COMPARATOR
Intervention: Control arm (surveillance information and overdose prevention resources)
Number of subjects: 0
Study 33110044 — intervention group
Group type: EXPERIMENTAL
Intervention: Fennel seed powder (2 gr, four capsules daily for 8 weeks)
Number of subjects: 80
Study 33110044 — intervention group
Group type: COMPARATOR
Intervention: Starch-containing capsules (2 gr, four capsules daily for 8 weeks)
Number of subjects: 80
Study 33347667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepilex Border Sacrum
Number of subjects: 12
Study 33347667 — intervention group
Group type: EXPERIMENTAL
Intervention: ALLEVYN Life Sacrum
Number of subjects: 12
Study 33347667 — intervention group
Group type: EXPERIMENTAL
Intervention: Optifoam Gentle Sacrum
Number of subjects: 12
Study 33347667 — intervention group
Group type: COMPARATOR
Intervention: No dressing
Number of subjects: 12
Study 36434348 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implants (type 1)
Number of subjects: 25
Study 36434348 — intervention group
Group type: COMPARATOR
Intervention: Delayed implants (type 4)
Number of subjects: 25
Study 33983993 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with Lactobacillus paracasei ssp. paracasei strain F19 (F19)
Number of subjects: 579
Study 33983993 — intervention group
Group type: EXPERIMENTAL
Intervention: Formula with bovine milk fat globule membranes (MFGM)
Number of subjects: 579
Study 33983993 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (SF)
Number of subjects: 579
Study 33983993 — intervention group
Group type: COMPARATOR
Intervention: Breastfed (BF) infants
Number of subjects: 579
Study 34049101 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 292
Study 34049101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 32700956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy for Seasonal Affective Disorder (CBT-SAD)
Number of subjects: 177
Study 32700956 — intervention group
Group type: COMPARATOR
Intervention: Light Therapy (LT)
Number of subjects: 177
Study 34655997 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiologist-patient consultation of US results
Number of subjects: 109
Study 34655997 — intervention group
Group type: COMPARATOR
Intervention: No radiologist-patient consultation of US results
Number of subjects: 109
Study 34556516 — intervention group
Group type: EXPERIMENTAL
Intervention: Nature hiking
Number of subjects: 26
Study 34556516 — intervention group
Group type: COMPARATOR
Intervention: Urban hiking
Number of subjects: 26
Study 35671774 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant plus capivasertib
Number of subjects: 140
Study 35671774 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant plus placebo
Number of subjects: 140
Study 32484623 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% colloidal oat eczema cream
Number of subjects: 61
Study 32484623 — intervention group
Group type: COMPARATOR
Intervention: Standard moisturizer
Number of subjects: 61
Study 35945486 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 64
Study 35945486 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 64
Study 34972764 — intervention group
Group type: EXPERIMENTAL
Intervention: emoTIC programme
Number of subjects: 385
Study 35392461 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral nudges (social peer comparison nudge, maintenance of professional certification incentive nudge, prior participation nudge)
Number of subjects: 421
Study 35392461 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior participation nudge
Number of subjects: 421
Study 35392461 — intervention group
Group type: EXPERIMENTAL
Intervention: Nudges (pooled analysis)
Number of subjects: 421
Study 35392461 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nudges)
Number of subjects: 421
Study 34510141 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic CBD 20 to 30 mg daily for 12 weeks
Number of subjects: 136
Study 34510141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 136
Study 33939897 — intervention group
Group type: EXPERIMENTAL
Intervention: l-carnitine (50 mg/kg/day, twice a day for three months)
Number of subjects: 55
Study 33939897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 32773375 — intervention group
Group type: EXPERIMENTAL
Intervention: Research summary with 2 sources of uncertainty
Number of subjects: 1727
Study 32773375 — intervention group
Group type: EXPERIMENTAL
Intervention: Research summary with 3 sources of uncertainty
Number of subjects: 1727
Study 32773375 — intervention group
Group type: COMPARATOR
Intervention: Research summary with 1 source of uncertainty
Number of subjects: 1727
Study 35815880 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-Code
Number of subjects: 17710
Study 35815880 — intervention group
Group type: COMPARATOR
Intervention: DNR
Number of subjects: 17710
Study 32907989 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL-C
Number of subjects: 300000
Study 32907989 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL-C
Number of subjects: 300000
Study 32907989 — intervention group
Group type: EXPERIMENTAL
Intervention: TGs
Number of subjects: 300000
Study 32907989 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 300000
Study 32907989 — intervention group
Group type: EXPERIMENTAL
Intervention: T2D
Number of subjects: 300000
Study 32907989 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP
Number of subjects: 300000
Study 32111307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis (5 × 10^8 cfu/kg)
Number of subjects: 360
Study 32111307 — intervention group
Group type: EXPERIMENTAL
Intervention: Montmorillonite (0.5 g/kg)
Number of subjects: 360
Study 32111307 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus subtilis (5 × 10^8 cfu/kg) and Montmorillonite (0.5 g/kg) combination
Number of subjects: 360
Study 33201054 — intervention group
Group type: EXPERIMENTAL
Intervention: Depatuxizumab mafodotin
Number of subjects: 2
Study 33201054 — intervention group
Group type: EXPERIMENTAL
Intervention: Epithelial debridement, aggressive lubrication, bandage contact lenses, reduction in chemotherapeutic dose to maintenance levels
Number of subjects: 2
Study 33201054 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunohistochemistry of the diseased epithelium
Number of subjects: 2
Study 32324880 — intervention group
Group type: EXPERIMENTAL
Intervention: Skull base chordomas with vertebrobasilar artery encasement (≥180o encirclement)
Number of subjects: 48
Study 32324880 — intervention group
Group type: COMPARATOR
Intervention: Control group of skull base chordomas with intradural extension
Number of subjects: 48
Study 35769693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual sufentanil tablet (SST)
Number of subjects: 36
Study 35769693 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care (patient-controlled epidural analgesia [PCEA] or PCA morphine)
Number of subjects: 36
Study 34742318 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran oil (RBO) 30g/day
Number of subjects: 40
Study 34742318 — intervention group
Group type: COMPARATOR
Intervention: Sunflower oil (SFO) 30g/day
Number of subjects: 40
Study 33064415 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 exercise sessions per week
Number of subjects: 3
Study 33064415 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 exercise sessions per week
Number of subjects: 3